Categories Earnings, Health Care
Earnings Summary: CooperCompanies reports higher Q4 revenue, adj. profit
CooperCompanies (NYSE: COO) has reported an increase in revenues and adjusted earnings for the fourth quarter of fiscal 2025. The medical device maker also issued guidance for the first quarter and fiscal 2026.
- Cooper’s fourth-quarter 2025 revenue increased 5% year-over-year to $1.07 billion; it was up 3% organically
- On a reported basis, Q4 earnings declined 27% from last year to $0.43 per share during the three months
- Adjusted earnings increased 11% annually to $1.15 per share in the October quarter
- Gross margin declined to 61% in Q4 from 67% in the year-ago quarter, driven by costs primarily related to reorganization activities
- Operating margin dropped to 13% from 19% in last year’s fourth quarter, reflecting costs related to reorganization
- For the first quarter of FY26, the management expects revenues in the range of $1.02 billion to $1.03 billion
- The guidance for Q1 adjusted earnings is between $1.02 per share and $1.04 per share
- For fiscal 2026, the company expects total revenue to be in the range of $4.299 billion to $4.338 billion
- It is looking for full-year adjusted earnings in the range of $4.45 per share to $4.60 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
Dollar Tree (DLTR), Dollar General (DG): Discount stores remain key gainers in a value-conscious landscape
Discount retailers Dollar Tree, Inc. (NASDAQ: DLTR) and Dollar General Corporation (NYSE: DG) have seen their stocks gain more than 30% in the past three months. The dollar stores continue
Everything you need to know about Aktis Oncology’s upcoming IPO
IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the